Quick Facts

• Addresses: Erectile Dysfunction (ED)
• Manages: Signs and symptoms of Benign Prostatic Hyperplasia (BPH)
• Used for: Pulmonary Arterial Hypertension (PAH) to improve exercise capacity

Tedallis (Tadalafil) is a prescription medication indicated for the management of specific conditions. Its primary uses are to address erectile dysfunction, a condition where an individual may experience difficulty in achieving or maintaining an erection suitable for sexual activity.

Furthermore, this treatment is used to relieve the signs and symptoms associated with benign prostatic hyperplasia (BPH), or an enlarged prostate, which can involve difficulties with urination.

For a separate indication, the medication is also prescribed for the treatment of pulmonary arterial hypertension (PAH). In this context, it is intended to help improve the ability to perform physical activity. These uses are established under regulatory review. The prescribing healthcare professional determines the appropriate use for each individual case.

Regulatory References

1. NIH MedlinePlus guidance

Tedallis (Tadalafil) is indicated for use in adults (18 years and older) for all approved indications. The official regulatory labeling defines mandatory exclusions and restrictions based on co-administered medicines, cardiovascular status, age, and organ function.

Contraindicated Populations (Must Not Use)	Condition-Specific Restrictions (Not Recommended)
Patients using any form of organic nitrate or Guanylate Cyclase (GC) stimulator (e.g., riociguat).	Patients with severe renal impairment (once-daily use).
Patients with a history of recent myocardial infarction (within 90 days) or stroke (within 6 months).	Patients with severe hepatic impairment (Child-Pugh Class C).
Patients with unstable angina or uncontrolled hypotension (<90/50 mmHg).	Children and adolescents (under 18 years) for ED/BPH indications.

Use is also contraindicated in patients with a history of vision loss due to Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION). For women, Tedallis is generally not intended for the ED/BPH indications, and use during pregnancy or lactation is not recommended due to insufficient data.

Interactions with other medicines and products

Tedallis (Tadalafil) has officially documented interaction patterns that primarily relate to its metabolic pathway and potentiation of blood pressure effects.

Prohibited Combinations and Timing Restrictions

Co-administration is strictly contraindicated with specific drug categories due to the risk of severe, symptomatic hypotension.

Classification	Interacting Agents	Official Restriction
Contraindicated	Organic Nitrates (e.g., Nitroglycerin)	Absolute Prohibition; requires 48-hour separation after the last dose.
Contraindicated	Guanylate Cyclase (GC) Stimulators (e.g., Riociguat)	Absolute Prohibition.

---

Metabolic and Pharmacodynamic Effects

The medicine's plasma exposure is predominantly regulated by the CYP3A4 enzyme. Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir) are officially documented to increase Tadalafil's concentration (AUC/Cmax) by reducing its clearance. Conversely, potent CYP3A4 Inducers (e.g., Rifampin) are noted to significantly decrease Tadalafil exposure. The clearance issues compounded by inhibitors necessitate specific dose limitations in patients with Severe Renal Insufficiency or Hepatic Impairment. Furthermore, Tadalafil exhibits a pharmacodynamic interaction with Alpha-Blockers (e.g., Doxazosin) and general Antihypertensive Agents, leading to an additive hypotensive effect. Consumption of substantial Alcohol (typically ge 5 units) is also officially noted to potentiate the vasodilatory effects, increasing the potential for orthostatic symptoms.

Tedallis acts as a selective inhibitor of the enzyme phosphodiesterase type 5 (PDE5), a metalloenzyme found predominantly in the smooth muscle cells of the corpus cavernosum, pulmonary vasculature, and prostatic tissue. Inhibition of PDE5 prevents the enzymatic hydrolysis of intracellular cyclic guanosine monophosphate (cGMP) to inactive 5 '-GMP.

Within the cell, cGMP is synthesized when nitric oxide (NO), released from endothelial and nerve terminals, activates soluble guanylate cyclase. The resulting increase in cGMP concentration activates cGMP-dependent protein kinase (PKG). This activation initiates a downstream cascade involving the phosphorylation of specific target proteins. The key intracellular consequence is the reduction of intracellular calcium ion concentrations through multiple mechanisms, including sequestering calcium into the sarcoplasmic reticulum and modulating calcium channel activity. Decreased intracellular Ca^2+ leads to the dephosphorylation of myosin light chain, resulting in smooth muscle cell relaxation. At a system level, this modulation enhances vasodilation in targeted vascular beds, increasing localized tissue perfusion and decreasing vascular resistance in organs like the pulmonary arteries and prostate.

Tedallis is administered exclusively by the oral route as a film-coated tablet in various strengths, including 2.5 mg, 5 mg, 10 mg, 20 mg, and 40 mg. The tablet must be swallowed whole and can be taken with or without food, as food intake does not significantly alter its absorption.

Usage for Erectile Dysfunction (ED) is defined by two distinct administration patterns. For as-needed (PRN) use, the typical starting dose is 10 mg, which may be adjusted up to a maximum of 20 mg or reduced to 5 mg. This PRN dose must be administered at least 30 minutes prior to anticipated activity, with administration limited to no more than once per day.

The once-daily regimen for ED and for Benign Prostatic Hyperplasia (BPH) is typically 5 mg, taken at approximately the same time each day to maintain consistent systemic levels. For the indication of Pulmonary Arterial Hypertension (PAH), the once-daily dose is 40 mg, which is explicitly instructed not to be divided. The maximum dose and frequency are reduced for patients with severe renal or hepatic impairment; for instance, the PRN dose for severe renal impairment is limited to 5 mg every 72 hours. Patients on a continuous regimen who miss a dose should resume taking the medicine at the next scheduled time without double-dosing.

Recent Clinical Evidence: Overview of Studies

Summary of Clinical Findings

Research has explored whether the medication leads to a reduction in pain, stiffness, and inflammation. It is classified as a nonsteroidal anti-inflammatory drug (NSAID), and studies have explored its interaction with prostaglandin synthesis pathways. This area of research has been a focus of study for its applications in managing chronic inflammatory conditions.

---

Studies in Osteoarthritis (OA)

Clinical studies have reported changes in joint function and swelling based on investigator assessments in individuals with Osteoarthritis. A key area of inquiry has been whether a reduction in morning stiffness is maintained over time. Trials typically assessed outcomes using standardized indices like the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and patient-reported pain scales.

Studies in Rheumatoid Arthritis (RA)

Research has evaluated the medication for its potential to affect pain levels in conditions such as rheumatoid arthritis. Research examined the use of the drug as a monotherapy and in combination with Disease-Modifying Antirheumatic Drugs (DMARDs).

Combination Therapy Trials

Research has explored whether the combination affects patient comfort and disease activity scores. In these trials, the drug was often studied alongside common DMARDs, such as methotrexate or sulfasalazine.

---

Safety and Tolerability Research

Safety studies have focused on characterizing the side effect profile. Common adverse events reported in the research included gastrointestinal discomfort and headache.

Long-Term Safety Data

Long-term studies have been conducted to evaluate safety beyond 12 weeks of treatment. Some studies have included monitoring of liver function and renal function over the study period. Research has included studies that compared the drug's incidence of gastrointestinal side effects against standard NSAIDs, examining tolerability across different dosing regimens.

Common questions about Tedallis (FAQ)

---

Q: Is Tedallis considered a long-term treatment or for temporary use?

Official documents describe Tedallis as suitable for both short-term, on-demand use as needed, and for a once-daily regimen. This daily administration pattern is used to maintain consistent levels for chronic conditions such as Benign Prostatic Hyperplasia (BPH) or Pulmonary Arterial Hypertension (PAH).

---

Q: How does Tedallis differ from other similar medicines in its class?

Official product information indicates that the active ingredient, Tadalafil, has a long duration of action due to its long terminal half-life, which is approximately 17.5 hours. This longer half-life is associated with an extended timeframe of response compared to some other medicines in the same pharmacological class.

---

Q: What is the expected duration of action of one dose of Tedallis?

Clinical studies report that the effect of a single dose of Tedallis is associated with a response lasting up to 36 hours in some individuals. This duration is linked to the medicine’s long half-life.

---

Q: Can Tedallis be taken with common over-the-counter pain relievers or cold medicines?

Interactions with common over-the-counter pain relievers like acetaminophen are not noted in the official prescribing information's warning section. However, the most critical interactions noted in the official label are with specific prescription drugs that affect blood pressure and the liver enzyme CYP3A4.

---

Q: What kind of scientific or clinical evidence supports the use of Tedallis?

The approved medical uses for Tedallis are supported by controlled clinical trials. These studies compare patient outcomes with the drug versus those receiving a placebo (an inactive substance) and reported positive changes in functional measures when compared to the placebo group.

---

Q: Do other medications need to be stopped when starting Tedallis?

Yes, medications containing organic nitrates or those classified as Guanylate Cyclase (GC) Stimulators are described in regulatory documents as strictly contraindicated and should be avoided. This is a mandatory restriction based on the risk of severe hypotension. If Tedallis has been taken, a separation of 48 hours is required before taking a nitrate.

---

Q: Is it possible to have an allergic reaction to Tedallis?

While not common, allergic reactions to Tedallis are possible. Official patient safety information describes the signs of a serious reaction, such as a severe rash, hives, or swelling of the face, lips, tongue, or throat, which require emergency medical attention.

---

Q: Is Tedallis appropriate for people over the age of 65?

Clinical studies found that the results for men over the age of 65 were consistent with the overall study population. This finding suggests the medicine is generally well tolerated by older adults.

---

Q: Is Tedallis considered a new drug, or has it been available for a long time?

The active ingredient in Tedallis, Tadalafil, has been available for a long time. It first received approval from the U.S. Food and Drug Administration (FDA) in November 2003 for one of its key indications.

---

Q: Where can a patient find information about the clinical trials conducted for Tedallis?

Patients can access detailed public information about the clinical trials supporting the medicine by searching government-maintained registries. These registries, such as ClinicalTrials.gov, can be searched using the drug’s name or active ingredient.

---

Q: Does Tedallis have any known potential for dependency or addiction?

Regulatory bodies do not classify Tedallis as a controlled substance, and it is not physically addictive. Official documents focus on the drug's classification and do not address every form of potential dependence.

---

Q: What does the term 'contraindication' mean in relation to Tedallis?

The term contraindication in official medicine labeling describes a situation in which the medicine should be avoided. For Tedallis, this prohibition is in place because using the medicine in those specific situations would pose a substantially increased risk of serious harm, such as severely low blood pressure.

Storage and Disposal Requirements

Official regulatory labeling dictates specific conditions for storing and disposing of tadalafil (the active ingredient in Tedallis) to maintain its safety and potency.

Storage Category	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C, 68 F to 77 F). Excursions are permitted between 15 C and 30 C.
Protection	Keep in the original container to protect from moisture and light. The product must not be frozen.
Child Safety	The medication must be kept out of the reach of children.

Disposal

Any unused or expired product must be disposed of in accordance with local requirements. Official guidance advises against flushing the tablets down the toilet. If a local take-back program is unavailable, the medication should be mixed with an unappealing substance (like dirt or used coffee grounds), sealed in a container, and discarded in the household trash.